New scan could spot breast cancer type without needle

NCT ID NCT07275463

ENROLLING_BY_INVITATION Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a radioactive imaging agent called [99mTc]Tc-DB8 to see if it can help doctors see breast cancer tumors and tell whether they are estrogen receptor positive or negative. Forty women with primary breast cancer will get one injection of the agent, followed by a SPECT/CT scan two hours later. The goal is to find out if this scan can provide useful information about the tumor type, which might guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Technetium-99m-labelled DB8 ([99mTc]Tc-DB8)
What this could lead to: If successful, this could lead to a new imaging method to better identify breast cancer types without invasive biopsies.
What could go wrong: This is a small, early-phase study with only 40 participants, so results may not apply to all patients. The imaging agent is experimental and its accuracy is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BREAST CANCER

Contacts and locations

Locations

Russia Tomsk NRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.